NHS England updates CDF List
NHS England updates CDF List
NHS England has updated the Cancer Drugs Fund List. The latest version (v1.357) was uploaded to the NHS England Website on Wednesday 2, April 2025.
The following changes have been introduced:
Brentuximab vedotin in combination with doxorubicin, vinblastine and dacarbazine (BRE15)
For treating adult patients with previously untreated stage III or IV Hodgkin lymphoma where the following criteria have been met
Recommended for routine commissioning, receiving CDF interim funding
Blinatumomab (BLI5)
Blinatumomab for treating ADULT patients in first morphological complete remission and without minimal residual disease after 1st line intensive induction and intensification chemotherapy for Philadelphia chromosome negative B-cell precursor acute lymphoblastic leukaemia where the following criteria have been met
Treatment criteria (#6 and 9) updated
Brexucabtagene autoleucel (BREX01a)
Brexucabtagene autoleucel modified CAR- T cells for treating relapsed/refractory Philadelphia negative or positive B cell precursor acute lymphoblastic leukaemia in patients aged 26 years and older where the following criteria are met: This form is for the approval of leucapheresis and manufacture of CAR-T cells. There is a second part to this form which relates to the subsequent infusion of CAR-T cells and this will be available after submission of the first part. The second part of the form (BREX01b) can only be completed as a continuation of this first part of the form (BREX01a) and BREX01b must be completed on infusion of CAR-T cells otherwise the treating Trust will not be reimbursed for the cost of brexucabtagene autoleucel
Treatment criterion (#2) updated